{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"NCT06179069","nct_id":"NCT06179069","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct06179069. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"ZL-1310 as a single-agent","label":"Dose Escalation: Part 1A","type":"EXPERIMENTAL"},{"description":"ZL-1310 in combination with Atezolizumab","label":"Dose Expansion: Part 1B","type":"EXPERIMENTAL"},{"description":"ZL-1310 in combination with Atezolizumab and Carboplatin as induction and followed by ZL-1310 and Atezolizumab as maintenance","label":"Dose Escalation: Part 1C","type":"EXPERIMENTAL"},{"description":"Dose level 1 of ZL-1310 established from single-agent dose-escalation","label":"Dose Expansion: Arm 1 (Part 2)","type":"EXPERIMENTAL"},{"description":"Dose level 2 of ZL-1310 established from single-agent dose escalation","label":"Dose Expansion: Arm 2 (Part 2)","type":"EXPERIMENTAL"},{"description":"ZL-1310 as a single agent","label":"Dose Extension: Arm 1 (Part 2)","type":"EXPERIMENTAL"},{"description":"Dose level 1 of ZL-1310 established from single agent dose escalation, in combination with Atezolizumab","label":"Doublet Dose Optimization: Arm 1 (Part 3A)","type":"EXPERIMENTAL"},{"description":"Dose level 2 of ZL-1310 established from single agent dose escalation in combination with Atezolizumab","label":"Doublet Dose Optimization: Arm 2 (Part 3A)","type":"EXPERIMENTAL"},{"description":"Dose level 1 of ZL-1310 established from single agent dose escalation in combination with Atezolizumab + Carboplatin induction followed by ZL-1310 + Atezolizumab as maintenance","label":"Triplet Dose Optimization: Arm 1 (Part 4A)","type":"EXPERIMENTAL"},{"description":"Dose level 2 of ZL-1310 established from single agent dose escalation, in combination with Atezolizumab + Carboplatin induction followed by ZL-1310 + atezolizumab as induction","label":"Triplet Dose Optimization: Arm 2 (Part 4A)","type":"EXPERIMENTAL"},{"description":"single-agent dose extension for Post-anti-DLL3","label":"Dose Extension: Part 2-1","type":"EXPERIMENTAL"},{"description":"Doublet dose extension for 1L maintenance only OR 1L induction + maintenance; to be initiated at the discretion of the sponsor based on the available emerging data.","label":"Doublet Dose Extension: Part 3B","type":"EXPERIMENTAL"},{"description":"Triplet dose extension for 1L induction + maintenance; to be initiated at the discretion of the sponsor based on the available emerging data.","label":"Triplet Dose Extension: Part 4B","type":"EXPERIMENTAL"}],"collaborators":["Zai Lab (US) LLC"],"completion_date":{"date":"2027-07-31","type":"ESTIMATED"},"conditions":["SCLC"],"enrollment":{"count":339,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"ZL-1310","otherNames":[],"type":"DRUG"},{"name":"Atezolizumab","otherNames":[],"type":"DRUG"},{"name":"Carboplatin","otherNames":[],"type":"DRUG"}],"last_update":"2026-10-16","lead_sponsor":"Zai Lab (Shanghai) Co., Ltd.","official_title":"An Open-label, Multicenter Study of ZL-1310 to Evaluate the Safety, Efficacy, and Pharmacokinetics in Participants With Small Cell Lung Cancer","overall_status":"RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2027-05-30","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Incidence of Dose Limiting Toxicities of ZL-1310 as a single agent (Part 1A), in combination with Atezolizumab (Part 1B), and in combination with atezolizumab and carboplatin (Part 1C)","timeFrame":"up to 24 months"},{"measure":"Incidence of Treatment Emergent Adverse-Events of ZL-1310 as a single agent (Part 1A), in combination with atezolizumab (Part 1B), and in combination with atezolizumab and carboplatin (Part 1C)","timeFrame":"up to 24 months"},{"measure":"Incidence of Serious Adverse Events of ZL-1310 as a single agent (Part 1A), in combination with atezolizumab (Part 1B), and in combination with atezolizumab and carboplatin (Part 1C)","timeFrame":"up to 24 months"},{"measure":"Incidence of Treatment Emergent Adverse Events of ZL-1310 as a single agent (Part 2), in combination with atezolizumab (Part 3) and in combination with atezolizumab and carboplatin (Part 4)","timeFrame":"up to 24 months"},{"measure":"Incidence of Serious Adverse-Events (SAEs) of ZL-1310 as a single agent (Part 2), in combination with atezolizumab (Part 3), and in combination with atezolizumab and carboplatin (Part 4)","timeFrame":"up to 24 months"},{"measure":"Antitumor activity per RECIST v1.1 by investigator's assessment of ZL-1310 as a single agent (Part 2), in combination with atezolizumab (Part 3), and in combination with atezolizumab and carboplatin (Part 4)","timeFrame":"up to 24 months"},{"measure":"Objective response rate (ORR) per RECIST v1.1 of ZL-1310 as a single agent (Part 2) and in combination with atezolizumab and carboplatin (Part 4)","timeFrame":"up to 24 months"},{"measure":"Disease control rate (DCR) per RECIST v1.1 of ZL-1310 in combination with atezolizumab","timeFrame":"up to 24 months"}],"references":[],"start_date":{"date":"2024-01-23","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of ZL-1310 in Subjects With Small Cell Lung Cancer","url":"https://clinicaltrials.gov/study/NCT06179069"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct06179069"}